219 related articles for article (PubMed ID: 34520280)
1. Generalized Anxiety Disorder 7-Item (GAD-7) Scores in Medically Authorized Cannabis Patients-Ontario and Alberta, Canada.
Lee C; Round JM; Hanlon JG; Hyshka E; Dyck JRB; Eurich DT
Can J Psychiatry; 2022 Jun; 67(6):470-480. PubMed ID: 34520280
[TBL] [Abstract][Full Text] [Related]
2. Changes in patient health questionnaire (PHQ-9) scores in adults with medical authorization for cannabis.
Round JM; Lee C; Hanlon JG; Hyshka E; Dyck JRB; Eurich DT
BMC Public Health; 2020 Jun; 20(1):987. PubMed ID: 32576158
[TBL] [Abstract][Full Text] [Related]
3. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder.
Ergisi M; Erridge S; Harris M; Kawka M; Nimalan D; Salazar O; Loupasaki K; Ali R; Holvey C; Coomber R; Platt M; Rucker JJ; Sodergren MH
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):487-495. PubMed ID: 34937473
[TBL] [Abstract][Full Text] [Related]
4. Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study.
Sachedina F; Chan C; Damji RS; de Sanctis OJ
Psychiatry Res; 2022 Jul; 313():114573. PubMed ID: 35598566
[TBL] [Abstract][Full Text] [Related]
5. Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada.
Lee C; Round JM; Klarenbach S; Hanlon JG; Hyshka E; Dyck JRB; Eurich DT
Harm Reduct J; 2021 Jun; 18(1):61. PubMed ID: 34103058
[TBL] [Abstract][Full Text] [Related]
6. Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada.
Dubois C; Fernandes H; Lin M; Martins KJB; Dyck JRB; Klarenbach SW; Richer L; Jess E; Hanlon JG; Hyshka E; Eurich DT
BMC Public Health; 2024 Mar; 24(1):859. PubMed ID: 38504198
[TBL] [Abstract][Full Text] [Related]
7. Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users.
Turna J; Simpson W; Patterson B; Lucas P; Van Ameringen M
J Psychiatr Res; 2019 Apr; 111():134-139. PubMed ID: 30738930
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry.
Rifkin-Zybutz R; Erridge S; Holvey C; Coomber R; Gaffney J; Lawn W; Barros D; Bhoskar U; Mwimba G; Praveen K; Symeon C; Sachdeva-Mohan S; Rucker JJ; Sodergren MH
Psychopharmacology (Berl); 2023 Aug; 240(8):1735-1745. PubMed ID: 37314478
[TBL] [Abstract][Full Text] [Related]
9. Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.
Lee C; Lin M; Martins KJB; Dyck JRB; Klarenbach S; Richer L; Jess E; Hanlon JG; Hyshka E; Eurich DT
BMC Public Health; 2021 May; 21(1):843. PubMed ID: 33933061
[TBL] [Abstract][Full Text] [Related]
10. A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance.
Murphy M; Erridge S; Holvey C; Coomber R; Rucker JJ; Sodergren MH
Neuropsychopharmacol Rep; 2024 Mar; 44(1):129-142. PubMed ID: 38155535
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients accessing medicinal cannabis in Australia: The QUEST initiative results of a 3-month follow-up observational study.
Tait MA; Costa DSJ; Campbell R; Norman R; Warne LN; Schug S; Rutherford C
PLoS One; 2023; 18(9):e0290549. PubMed ID: 37672515
[TBL] [Abstract][Full Text] [Related]
12. Cohort study of medical cannabis authorisation and healthcare utilisation in 2014-2017 in Ontario, Canada.
Eurich D; Lee C; Zongo A; Minhas-Sandhu JK; Hanlon JG; Hyshka E; Dyck J
J Epidemiol Community Health; 2020 Mar; 74(3):299-304. PubMed ID: 31831619
[TBL] [Abstract][Full Text] [Related]
13. A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.
Gao K; Ganocy SJ; Conroy C; Brownrigg B; Serrano MB; Calabrese JR
Psychopharmacology (Berl); 2017 Aug; 234(15):2233-2244. PubMed ID: 28536866
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7).
Toussaint A; Hüsing P; Gumz A; Wingenfeld K; Härter M; Schramm E; Löwe B
J Affect Disord; 2020 Mar; 265():395-401. PubMed ID: 32090765
[TBL] [Abstract][Full Text] [Related]
15. Canada's cannabis legalization and drivers' traffic-injury presentations to emergency departments in Ontario and Alberta, 2015-2019.
Callaghan RC; Sanches M; Vander Heiden J; Asbridge M; Stockwell T; Macdonald S; Peterman BH; Kish SJ
Drug Alcohol Depend; 2021 Nov; 228():109008. PubMed ID: 34508959
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of the generalized anxiety disorder 7-item scale and the Edinburgh Postnatal Depression Scale as screening tools for generalized anxiety disorder in pregnancy and the postpartum period.
Simpson W; Glazer M; Michalski N; Steiner M; Frey BN
Can J Psychiatry; 2014 Aug; 59(8):434-40. PubMed ID: 25161068
[TBL] [Abstract][Full Text] [Related]
17. Cohort study of medical cannabis authorization and motor vehicle crash-related healthcare visits in 2014-2017 in Ontario, Canada.
Lee C; Voaklander D; Minhas-Sandhu JK; Hanlon JG; Hyshka E; Dyck JRB; Eurich DT
Inj Epidemiol; 2021 Apr; 8(1):33. PubMed ID: 33906699
[TBL] [Abstract][Full Text] [Related]
18. Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study.
Bapir L; Erridge S; Nicholas M; Pillai M; Dalavaye N; Holvey C; Coomber R; Hoare J; Khan S; Weatherall MW; Rucker JJ; Platt M; Sodergren MH
Expert Rev Neurother; 2023 Mar; 23(3):281-295. PubMed ID: 36803620
[TBL] [Abstract][Full Text] [Related]
19. An interrupted time series evaluation of the effect of cannabis legalization on intentional self-harm in two Canadian provinces: Ontario and Alberta.
Cusimano MD; Carpino M; Walker M; Saarela O; Mann R
Health Promot Chronic Dis Prev Can; 2023 Sep; 43(9):403-408. PubMed ID: 37707352
[TBL] [Abstract][Full Text] [Related]
20. Substance Use Disorders and Psychoactive Drug Poisoning in Medically Authorized Cannabis Patients: Longitudinal Cohort Study.
Zongo A; Lee C; El-Mourad J; Dyck JRB; Hyshka E; Hanlon JG; Eurich DT
Can J Psychiatry; 2022 Jul; 67(7):544-552. PubMed ID: 34806435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
